These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9707267)

  • 21. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
    Pitt B
    Am J Cardiol; 1997 Mar; 79(5A):24-8. PubMed ID: 9127618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations.
    Mancini GB
    Clin Invest Med; 2000 Apr; 23(2):144-61. PubMed ID: 10852664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
    Ferrari R; Ceconi C; Curello S; Pepi P; Mazzoletti A; Visioli O
    Cardiovasc Drugs Ther; 1996 Nov; 10 Suppl 2():639-47. PubMed ID: 9115958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the renin-angiotensin system in vascular health: use of ACE inhibition to improve vascular function.
    Izzo JL
    Heart Dis; 2000; 2(5):380-3. PubMed ID: 11728286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin converting enzyme inhibition and coronary artery disease.
    Pepine CJ
    J Hypertens Suppl; 1994 Jul; 12(4):S65-71. PubMed ID: 7965277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin.
    Varin R; Mulder P; Tamion F; Richard V; Henry JP; Lallemand F; Lerebours G; Thuillez C
    Circulation; 2000 Jul; 102(3):351-6. PubMed ID: 10899101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.
    Lüscher TF; Yang Z
    Drugs; 1993; 46 Suppl 2():121-32. PubMed ID: 7512465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do ACE inhibitors modulate atherosclerosis?
    Curzen NP; Fox KM
    Eur Heart J; 1997 Oct; 18(10):1530-5. PubMed ID: 9347263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelial dysfunction: its pathogenic role in atherosclerosis and its reversal by ACE inhibition.
    Neutel JM
    Postgrad Med; 2000 Oct; 108(5 Suppl):4-11. PubMed ID: 19667535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for ACE inhibition as an anti-ischaemic therapy.
    Pepine CJ
    Eur Heart J; 1998 Jul; 19 Suppl G():G34-40. PubMed ID: 9717054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial function and dysfunction in heart failure.
    Ferrari R; Bachetti T; Agnoletti L; Comini L; Curello S
    Eur Heart J; 1998 Jul; 19 Suppl G():G41-7. PubMed ID: 9717055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.
    Dzau VJ; Bernstein K; Celermajer D; Cohen J; Dahlöf B; Deanfield J; Diez J; Drexler H; Ferrari R; van Gilst W; Hansson L; Hornig B; Husain A; Johnston C; Lazar H; Lonn E; Lüscher T; Mancini J; Mimran A; Pepine C; Rabelink T; Remme W; Ruilope L; Ruzicka M; Schunkert H; Swedberg K; Unger T; Vaughan D; Weber M;
    Am J Cardiol; 2001 Nov; 88(9A):1L-20L. PubMed ID: 11694220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
    Landmesser U; Drexler H
    J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ACE inhibitors on endothelial dysfunction: unanswered questions and implications for further investigation and therapy.
    Pitt B
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):469-73. PubMed ID: 8924062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards 2001: will ACE inhibitors have a role in atherosclerosis treatment?
    Sharpe N
    Int J Clin Pract Suppl; 1998 May; 94():26-31. PubMed ID: 9926442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial dysfunction: the role and impact of the renin-angiotensin system.
    Lüscher TF
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i20-2:discussion i50. PubMed ID: 10956315
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure.
    Drexler H; Kurz S; Jeserich M; Münzel T; Hornig B
    Am J Cardiol; 1995 Nov; 76(15):13E-18E. PubMed ID: 7484881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary endothelial function in health and disease.
    Burnett JC
    Drugs; 1997; 53 Suppl 1():20-9. PubMed ID: 9034752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.